⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Shanghai Pharmaceuticals Holding Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Shanghai Pharmaceuticals Holding Co., Ltd.
↗Shanghai, China
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) is a leading, vertically-integrated Chinese pharmaceutical group. The company operates across the entire healthcare value chain, including research and development, manufacturing, distribution, and a vast retail pharmacy network.
SPH is a major player in the Chinese market, focusing on innovative drugs, traditional Chinese medicines, and chemical drugs. Its therapeutic portfolio spans cardiovascular, digestive and metabolic, anti-infection, central nervous system, oncology, and immunomodulatory diseases. The company is dual-listed on the Shanghai and Hong Kong Stock Exchanges.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Integrated Pharma (Manufacturing & Distribution)
SIZE & FINANCIALS
Employees:10000+
Revenue:$40B+
Founded:1994
Ownership:public
Status:operating
STOCK
Exchange:SSE, HKEX
Ticker:601607 (SSE), 02607 (HKEX)
Market Cap:$8.35B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Monoclonal antibody, ADC, Traditional Chinese Medicine
Active Trials:331
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Shanghai Pharma Biotherapeutics USA Inc. (SPHBio)
Key Partnerships:HUTCHMED (formerly joint venture partner)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Da Wei Liu - CEO
LINKS
Website:sphchina.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shanghai Pharmaceuticals Holding Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.